Dr. Cohen received his M.D. from the University of Pennsylvania School of Medicine. He completed internal medicine residency training at the Massachusetts General Hospital and then obtained fellowship training in adult hematology and medical oncology at the Dana-Farber/Brigham and Women’s and Massachusetts General Hospital combined fellowship program. Following fellowship, he became an Instructor at the MGH where his research focused on the role of angiogenic progenitor cells in tumor vascular biology. He was then recruited to the University of Chicago in 2007 as an Assistant Professor of Medicine. He is currently an Associate Professor of Medicine at the University of Chicago. He serves as Program Director of the Adult Hematology/Oncology Fellowship Program and is Program Leader of Classical Hematology. He is also Director of the University of Chicago HHT Center of Excellence. Clinically he cares for patients with HHT as well as disorders of thrombosis and hemostasis.
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11; 9(21):5665-5675.
PMID: 40720747
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Mar; 23(3):113-130.
PMID: 40073837
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. Clin Cancer Res. 2023 12 15; 29(24):5031-5037.
PMID: 37498309
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors.
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30600.
PMID: 37534382
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023 08 03; 25(8):1530-1545.
PMID: 36808285
Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.
Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance. Heliyon. 2023 May; 9(5):e16006.
PMID: 37163164
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial.
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial. Clin Infect Dis. 2023 02 08; 76(3):e1-e9.
PMID: 36124697
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. J Clin Oncol. 2023 04 01; 41(10):1921-1932.
PMID: 36548930
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 12; 20(12):1339-1362.
PMID: 36509072
Comparison of Care Quality Metrics in 2-Sided Risk Medicare Advantage vs Fee-for-Service Medicare Programs.
Comparison of Care Quality Metrics in 2-Sided Risk Medicare Advantage vs Fee-for-Service Medicare Programs. JAMA Netw Open. 2022 12 01; 5(12):e2246064.
PMID: 36508218